adjuvant chemotherapy

Adjuvant chemotherapy in the context of the Phase III clinical trial (NCT01231828) led by Xiaoming Xie for early-stage triple-negative breast cancer (TNBC) refers to the systemic administration of cytotoxic drug regimens following surgical intervention. The protocol specifies the use of the TC regimen (docetaxel and cyclophosphamide) for Stage I patients and the TAC regimen (docetaxel, doxorubicin, and cyclophosphamide) for Stage II patients. These regimens are designed to eliminate micrometastases and reduce the high risk of recurrence associated with the aggressive TNBC subtype. Docetaxel acts as a microtubule stabilizer, cyclophosphamide as a DNA alkylating agent, and doxorubicin as a DNA intercalator and topoisomerase II inhibitor, collectively providing a multi-targeted approach to preventing disease relapse.

Other names

adjuvant chemotherapy-Xiaoming Xie-breast cancer (triple-negative)docetaxel + cyclophosphamidedocetaxel + doxorubicin + cyclophosphamide